Dendritic cells pulsed with leukemia cell-derived exosomes more efficiently induce antileukemic immunities

PLoS ONE

Volumn 9, Issue 3, 2014, Pages

  Yao, Ye ^a   Wang, Chun ^b   Wei, Wei ^a   Shen, Chang ^b   Deng, Xiaohui ^a   Chen, Linjun ^a   Ma, Liyuan ^c   Hao, Siguo ^a  

^a XINHUA HOSPITAL AFFILIATED TO SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b SHANGHAI JIAO TONG UNIVERSITY   (China)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

HEAT SHOCK PROTEIN 70; INTERCELLULAR ADHESION MOLECULE 1;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTILEUKEMIC IMMUNITY; ARTICLE; CELL SIZE; CELL VACUOLE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY ASSAY; DENDRITIC CELL; EXOSOME; FEMALE; IMMUNE RESPONSE; LEUKEMIA; LEUKEMIA CELL; LEUKEMIA CELL DERIVED EXOSOME; MOUSE; NONHUMAN; TRANSMISSION ELECTRON MICROSCOPY; TUMOR IMMUNITY; WESTERN BLOTTING; ANIMAL; CYTOLOGY; HUMAN; IMMUNOLOGY; K562 CELL LINE; PATHOLOGY; TRANSPORT AT THE CELLULAR LEVEL; ULTRASTRUCTURE;

ANIMALS; BIOLOGICAL TRANSPORT; DENDRITIC CELLS; EXOSOMES; FEMALE; HUMANS; K562 CELLS; LEUKEMIA; MICE; MICROSCOPY, ELECTRON, TRANSMISSION; T-LYMPHOCYTES, CYTOTOXIC;

EID: 84897980908     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0091463     Document Type: Article

References (35)

1. San Miguel JF, Martinez A, Macedo A, Vidriales MB, Lopez-Berges C, et al. (1997) Immunophenotyping investigation of minimal residual disease is a useful approach for predicting relapse in acute myeloid leukemia patients. Blood 90: 2465-2470. (Pubitemid 27392732)
2. Oka Y, Tsuboi A, Taguchi T, Osaki T, Kyo T, et al. (2004) Induction of WT1 (Wilms' tumor gene)-specific cytotoxic T lymphocytes by WT1 peptide vaccine and the resultant cancer regression. Proc Natl Acad Sci U S A 101: 13885-13890. (Pubitemid 39298502)
3. Mailander V, Scheibenbogen C, Thiel E, Letsch A, Blau IW, et al. (2004) Complete remission in a patient with recurrent acute myeloid leukemia induced by vaccination with WT1 peptide in the absence of hematological or renal toxicity. Leukemia 18: 165-166. (Pubitemid 38159453)
4. Barrett AJ, Le Blanc K (2010) Immunotherapy prospects for acute myeloid leukaemia. Clin Exp Immunol 161: 223-232.
5. Denzer K, Kleijmeer MJ, Heijnen HF, Stoorvogel W, Geuze HJ (2000) Exosome: from internal vesicle of the multivesicular body to intercellular signaling device. J Cell Sci 113 Pt 19: 3365-3374.
6. Thery C, Zitvogel L, Amigorena S (2002) Exosomes: composition, biogenesis and function. Nat Rev Immunol 2: 569-579. (Pubitemid 37328732)
7. Andre F, Schartz NE, Chaput N, Flament C, Raposo G, et al. (2002) Tumor-derived exosomes: a new source of tumor rejection antigens. Vaccine 20 Suppl 4: A28-31. (Pubitemid 35452633)
8. Kim JV, Latouche JB, Riviere I, Sadelain M (2004) The ABCs of artificial antigen presentation. Nat Biotechnol 22: 403-410. (Pubitemid 38451370)
9. Chaput N, Schartz NE, Andre F, Zitvogel L (2003) Exosomes for immunotherapy of cancer. Adv Exp Med Biol 532: 215-221. (Pubitemid 37176789)
10. Thery C, Duban L, Segura E, Veron P, Lantz O, et al. (2002) Indirect activation of naive CD4+ T cells by dendritic cell-derived exosomes. Nat Immunol 3: 1156-1162. (Pubitemid 35469700)
11. Andre F, Schartz NE, Movassagh M, Flament C, Pautier P, et al. (2002) Malignant effusions and immunogenic tumour-derived exosomes. Lancet 360: 295-305. (Pubitemid 34874721)
12. Wolfers J, Lozier A, Raposo G, Regnault A, Thery C, et al. (2001) Tumor-derived exosomes are a source of shared tumor rejection antigens for CTL cross-priming. Nat Med 7: 297-303. (Pubitemid 32224344)
13. Altieri SL, Khan AN, Tomasi TB (2004) Exosomes from plasmacytoma cells as a tumor vaccine. J Immunother 27: 282-288. (Pubitemid 38833324)
14. Hao S, Bai O, Yuan J, Qureshi M, Xiang J (2006) Dendritic cell-derived exosomes stimulate stronger CD8+ CTL responses and antitumor immunity than tumor cell-derived exosomes. Cell Mol Immunol 3: 205-211.
15. Taylor DD, Gercel-Taylor C, Lyons KS, Stanson J, Whiteside TL (2003) T-cell apoptosis and suppression of T-cell receptor/CD3-zeta by Fas ligand-containing membrane vesicles shed from ovarian tumors. Clin Cancer Res 9: 5113-5119. (Pubitemid 37413559)
16. Zitvogel L, Regnault A, Lozier A, Wolfers J, Flament C, et al. (1998) Eradication of established murine tumors using a novel cell-free vaccine: dendritic cell-derived exosomes. Nat Med 4: 594-600. (Pubitemid 28237359)
17. Hao S, Bai O, Li F, Yuan J, Laferte S, et al. (2007) Mature dendritic cells pulsed with exosomes stimulate efficient cytotoxic T-lymphocyte responses and antitumour immunity. Immunology 120: 90-102. (Pubitemid 44950474)
18. Lozzio CB, Lozzio BB (1975) Human chronic myelogenous leukemia cell-line with positive Philadelphia chromosome. Blood 45: 321-334.
19. Shen C, Hao SG, Zhao CX, Zhu J, Wang C (2011) Antileukaemia immunity: effect of exosomes against NB4 acute promyelocytic leukaemia cells. J Int Med Res 39: 740-747.
20. Merchant ML, Powell DW, Wilkey DW, Cummins TD, Deegens JK, et al. (2010) Microfiltration isolation of human urinary exosomes for characterization by MS. Proteomics Clin Appl 4: 84-96.
21. Thery C, Amigorena S, Raposo G, Clayton A (2006) Isolation and characterization of exosomes from cell culture supernatants and biological fluids. Curr Protoc Cell Biol Chapter 3: Unit 3 22.
22. Savina A, Furlan M, Vidal M, Colombo MI (2003) Exosome release is regulated by a calcium-dependent mechanism in K562 cells. J Biol Chem 278: 20083-20090. (Pubitemid 36799202)
23. Abache T, Le Naour F, Planchon S, Harper F, Boucheix C, et al. (2007) The transferrin receptor and the tetraspanin web molecules CD9, CD81, and CD9P-1 are differentially sorted into exosomes after TPA treatment of K562 cells. J Cell Biochem 102: 650-664. (Pubitemid 47557419)
24. Akira S, Takeda K, Kaisho T (2001) Toll-like receptors: critical proteins linking innate and acquired immunity. Nat Immunol 2: 675-680. (Pubitemid 32747155)
25. Knight SC, Iqball S, Roberts MS, Macatonia S, Bedford PA (1998) Transfer of antigen between dendritic cells in the stimulation of primary T cell proliferation. Eur J Immunol 28: 1636-1644. (Pubitemid 28221168)
26. Banchereau J, Steinman RM (1998) Dendritic cells and the control of immunity. Nature 392: 245-252. (Pubitemid 28155090)
27. Prasad SJ, Farrand KJ, Matthews SA, Chang JH, McHugh RS, et al. (2005) Dendritic cells loaded with stressed tumor cells elicit long-lasting protective tumor immunity in mice depleted of CD4+CD25+ regulatory T cells. J Immunol 174: 90-98. (Pubitemid 40007395)
28. Parkhurst MR, DePan C, Riley JP, Rosenberg SA, Shu S (2003) Hybrids of dendritic cells and tumor cells generated by electrofusion simultaneously present immunodominant epitopes from multiple human tumor-associated antigens in the context of MHC class I and class II molecules. J Immunol 170: 5317-5325. (Pubitemid 36554767)
29. Avigan D, Vasir B, Gong J, Borges V, Wu Z, et al. (2004) Fusion cell vaccination of patients with metastatic breast and renal cancer induces immunological and clinical responses. Clin Cancer Res 10: 4699-4708. (Pubitemid 38955520)
30. Dorfel D, Appel S, Grunebach F, Weck MM, Muller MR, et al. (2005) Processing and presentation of HLA class I and II epitopes by dendritic cells after transfection with in vitro-transcribed MUC1 RNA. Blood 105: 3199-3205.
31. Fukui M, Nakano-Hashimoto T, Okano K, Maruta Y, Suehiro Y, et al. (2004) Therapeutic effect of dendritic cells loaded with a fusion mRNA encoding tyrosinase-related protein 2 and enhanced green fluorescence protein on B16 melanoma. Tumour Biol 25: 252-257. (Pubitemid 40082327)
32. Delluc S, Tourneur L, Michallet AS, Boix C, Varet B, et al. (2005) Autologous peptides eluted from acute myeloid leukemia cells can be used to generate specific antileukemic CD4 helper and CD8 cytotoxic T lymphocyte responses in vitro. Haematologica 90: 1050-1062. (Pubitemid 41323504)
33. Ostankovitch M, Buzyn A, Bonhomme D, Connan F, Bouscary D, et al. (1998) Antileukemic HLA-restricted T-cell clones generated with naturally processed peptides eluted from acute myeloblastic leukemia blasts. Blood 92: 19-24. (Pubitemid 28303170)
34. Chaput N, Schartz NE, Andre F, Taieb J, Novault S, et al. (2004) Exosomes as potent cell-free peptide-based vaccine. II. Exosomes in CpG adjuvants efficiently prime naive Tc1 lymphocytes leading to tumor rejection. J Immunol 172: 2137-2146. (Pubitemid 38182359)
35. Yao Y, Chen L, Wei W, Deng X, Ma L, et al. (2013) Tumor cell-derived exosome-targeted dendritic cells stimulate stronger CD8+ CTL responses and antitumor immunities. Biochem Biophys Res Commun 436: 60-65.